We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Data presented at the conference will include recent results from Selvita’s discovery phase project targeting cancer immunometabolism – a dual A2A/A2B adenosine receptor antagonist, as well as cancer immunotherapy – a novel class of small molecule direct